Safety and tolerability of intratumorally administered OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: A phase I dose escalation clinical study.

Jing Huang,Bo-lin Zhang,Jia-Lin Tang,Q. Chang,Rui Zhang,C. Geng,Dawei Wu,L. Qi,Xiangyong Gu,Binlei Liu
DOI: https://doi.org/10.1200/jco.2020.38.15_suppl.3139
2020-05-20
Abstract:3139Background: There have been limited reports concerning treatment outcomes of oncolytic viruses in solid tumors other than melanoma. OH2 is a genetically engineered oncolytic herpes simplex viru...
Medicine
What problem does this paper attempt to address?